Narrative review on efficacy and safety of anti-angiogenesis in combination with immunotherapy in the treatment of breast cancer

作者：Xueman Deng, Jieqiong Liu · 发表于：Translational Breast Cancer Research · 年份：2024 · DOI：10.21037/tbcr-24-21 · 被引用次数：7 · 研究领域：Angiogenesis and VEGF in Cancer、Cancer Immunotherapy and Biomarkers、Immunotherapy and Immune Responses

Background and Objective: Breast cancer was the second frequently diagnosed cancer in 2022 among all cancers. Besides classical chemotherapy and radiation, immunotherapy and targeted therapy are both identical treatment options for patients with advanced breast cancer. Immunotherapy is a therapeutic approach to control and eliminate tumors by restarting and maintaining the tumor-immunity cycle and restoring the body's normal anti-tumor immune response. Immunotherapy alone or in combination with other therapies has been shown to be clinically beneficial in a variety of solid tumors with a manageable safety profile. However, immunotherapy alone cannot fully satisfy the therapeutic needs for patients with breast cancer. Therefore, there is an urgent need for immunotherapy to be combined with other therapeutic approaches to increase treatment efficacy. Methods: We systematically searched PubMed database for relevant studies published over the past 5 years. Articles were screened for eligibility and key data extracted. Key Content and Findings: We assess the current breast cancer treatment landscape, summarizing efficacy and safety of recent immunotherapy, chemotherapy combined with immunotherapy, immunotherapy combined with anti-angiogenic therapy. In the treatment of breast cancer, aiming to promote further research and applications of this novel treatment regimen in patients with breast cancer. Since anti-angiogenic therapy can reprogramme the tumor immune microenvironment, imm...